Description
Goal for ASB 301
- Evaluate fluroquinolone use and appropriateness for UTI and CAP
- Focus on ED
- Prescriber level data/peer comparison
- Focus on ED
- Get pharmacist to attend meetings and work as a team
Project Resources
Core Elements
Education
Educating clinicians about resistance and optimal prescribing.
PDSA Cycles
Progress on PDSA Cycle 1
Review:
- Had a lot of newborn respiratory issues
- Not a lot of pneumonia
- Doing well with ASB/UTI
- Fluroquinolone use (mainly cipro)
- in 90s, drug manufacturers promoted use
- Good urinary penetration, but don’t need this level of antibiotic agent for uncomplicated UTI
- Could be one provider
- Go through cases and look who doctor was
- Get list of visit numbers given cipro
- 11 charts to look through
- Go through cases and look who doctor was
- Ciprofloxacin – more at discharge, could be ED issue
- in 90s, drug manufacturers promoted use
- Show 11/15 presentation recording on medstaff
Goal:
- Evaluate fluroquinolone use and appropriateness for UTI and CAP
- Focus on ED
- Prescriber level data/peer comparison
- Focus on ED
- Get pharmacist to attend meetings and work as a team
Data collection:
- 3 urine cases per month
- Pneumonia:
- Where can you get the data?
- Assistant looks through reportable diseases daily
- Reporting to public health, medstaff
- Could pick out pneumonias during daily search
- in-patient admits only
- For ED – could look at ICD 10 codes
- Assistant currently looks at chief diagnosis/complaint
- Assistant looks through reportable diseases daily
- Looking for any pneumonia
- Should be enough to get 3 per month if ED is included
- Look at ER tracking board daily – capture as they come in
- Re-evaluate in a few months to see if meeting goals
- Could look at lab department
- Should be enough to get 3 per month if ED is included
- Where can you get the data?
Final data approach:
- Daily review of ED (track board) and inpatient (current process) to capture all pneumonia